Abstract
Introduction
Paragangliomas are infrequent neuroendocrine tumours whose only criterion for malignancy is presence of metastases; thus, all paragangliomas show malignant potential. Actually, different risk factors have been analyzed to predict metastases but they remain unclear.
Purpose
To analyze clinical, histological, and genetic factors to predict the occurrence of metastasis.
Patients and method
A multicentre retrospective observational analysis was performed between January 1990 and July 2019. Patients diagnosed with paraganglioma were selected. Clinical, histological, and genetic features were analyzed for the prediction of malignancy.
Results
A total of 83 patients diagnosed with paraganglioma were included, of which nine (10.8%) had malignant paraganglioma. Tumour size was greater in malignant tumours than in benign (6 cm vs. 4 cm, respectively; p = 0.027). The most frequent location of malignancy was the thorax-abdomen-pelvis area observed in six cases (p = 0.024). No differences were observed in histological differentiation, age, symptoms, and catecholaminergic production. The most frequent genetic mutation was SDHD followed by SDHB but no differences were observed between benign and malignant tumours. In the univariate analysis for predictive factors for malignancy, location, tumour size, and histological differentiation showed statistical significance (p = 0.025, p = 0.014, and p = 0.046, respectively); however, they were not confirmed as predictive factors for malignancy in the multivariate analysis.
Conclusion
In this study, no risk factors for malignancy have been established; therefore, we recommend follow-up of all patients diagnosed with paraganglioma.
Similar content being viewed by others
References
Thompson LD, Young WF, Kawashima A, Komminoth P (2004) Malignant adrenal phaeochromocytoma. In: DeLellis RA, Lloyd RV (eds) World health organization classification of tumours pathology & genetics tumours of endocrine organs, 3rd edn. IARC, Lyon, pp 147–150
Gunawardane PTK, Grossman A (2017) Phaeochromocytoma and paraganglioma. Adv Exp Med Biol 956:239–259. https://doi.org/10.1007/5584_2016_76
Lloyd R, Osamura R, Klöppel G, Rosai J (2017) WHO classification of tumours of endocrine organs, vol. 10, 4th edn. IARC Press, Lyon
Thompson L, Young W, Kawashima A, Komminoth P, Tischler A (2004) Malignant adrenal phaeochromocytoma Pathology and genetics of tumours of endocrine organs. IARC Press, Lyon
Eisenhofer G, Tischler AS, de Krijger RR (2012) Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification. Endocr Pathol 23(1):4–14
Hamidi O, Young WF Jr, Iniguez-Ariza NM, Kittah NE, Gruber L, Bancos C et al (2017) Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J Clin Endocrinol Metab 102(9):3296–3305
Korevaar TI, Grossman AB (2011) Pheochromocytomas and paragangliomas: assessment of malignant potential. Endocrine 40(3):354–365
Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T et al (2011) Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 96(3):717–725
O’Riordain DS, Young WF Jr, Grant CS, Carney JA, Van Heerden JA (1996) Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J Surg 20(7):916–922
van der Harst E, de Herder WW, de Krijger RR, Bruining HA, Bonjer HJ, Lamberts SW, van den Meiracker AH, Stijnen TH, Boomsma F (2002) The value of plasma markers for the clinical behaviour of phaeochromocytomas. Eur J Endocrinol 147(1):85–94. https://doi.org/10.1530/eje.0.1470085
Kim KY, Kim JH, Hong AR, Seong MW, Lee KE, Kim SJ, Kim SW, Shin CS, Kim SY (2016) Disentangling of malignancy from benign pheochromocytomas/paragangliomas. PLoS One 11(12):e0168413. https://doi.org/10.1371/journal.pone.0168413
Kimura N, Watanabe T, Noshiro T, Shizawa S, Miura Y (2005) Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol 16(1):23–32
Welander J, Soderkvist P, Gimm O (2011) Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer 18(6):R253–R276
Kimura N, Takekoshi K, Naruse M (2018) Risk stratification on pheochromocytoma and paraganglioma from laboratory and clinical medicine. J Clin Med 7(9):242
Plouin P, Amar L, Dekkers O, Fassnacht M, Gimenez-Roqueplo A, Lenders J et al (2016) European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol 174(5):G1–G10
Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, Kakoi N et al (2014) Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer 21(3):405–414
Intenzo CM, Jabbour S, Lin HC, Miller JL, Kim SM, Capuzzi DM et al (2007) Scintigraphic imaging of body neuroendocrine tumors. Radiographics 27(5):1355–69
Jansen JC, van den Berg R, Kuiper A, van der Mey AG, Zwinderman AH, Cornelisse CJ (2000) Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal. Cancer 88(12):2811–2816
Lack EE (1997) Tumors of the adrenal gland and extra-adrenal paraganglia. In: Rosai J (ed) Atlas of tumor pathology. Ser 3, fasc 19. Armed Forces Institute of Pathology, Washington, DC, p 303–409
Andersen KF, Altaf R, Krarup-Hansen A, Kromann-Andersen B, Horn T, Christensen NJ et al (2011) Malignant pheochromocytomas and paragangliomas–the importance of a multidisciplinary approach. Cancer Treat Rev 37(2):111–119
Lee JA, Duh QY (2008) Sporadic paraganglioma. World J Surg 32(5):683–687
Harari A, Inabnet WB III (2011) Malignant pheochromocytoma: a review. Am J Surg 201(5):700–708
Amar L, Lussey-Lepoutre C, Lenders J, Djadi-Prat J, Plouin P-F, Steichen O (2016) Recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysis. Eur J Endocrinol 175:R135–R145
Feng F, Zhu Y, Wang X, Wu Y, Zhou W, Jin X et al (2011) Predictive factors for malignant pheochromocytoma: analysis of 136 patients. J Urol 185(5):1583–1590
Gunawardane K, Grossman A (2017) The clinical genetics of phaeochromocytoma and paraganglioma. Arch Endocrinol Metabol 61(5):490–500
Al-Harthy M, Al-Harthy S, Al-Otieschan A, Velagapudi S, Alzahrani AS (2009) Comparison of pheochromocytomas and abdominal and pelvic paragangliomas with head and neck paragangliomas. Endocr Pract 15(3):194–202
Agarwal A, Mehrotra PK, Jain M, Gupta SK, Mishra A, Chand G et al (2010) Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy? World J Surg 34(12):3022–3028
Thompson LD (2002) Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26(5):551–566
de Wailly P, Oragano L, Radé F, Beaulieu A, Arnault V, Levillain P et al (2012) Malignant pheochromocytoma: new malignancy criteria. Langenbeck’s archives of surgery 397(2):239–246
Wu D, Tischler AS, Lloyd RV, DeLellis RA, de Krijger R, van Nederveen F et al (2009) Observer variation in the application of the pheochromocytoma of the adrenal gland scaled score. Am J Surg Pathol 33(4):599–608
Neumann HP, Pawlu C, Pęczkowska M, Bausch B, McWhinney SR, Muresan M et al (2004) Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292(8):943–951
Sbardella E, Cranston T, Isidori AM, Shine B, Pal A, Jafar-Mohammadi B et al (2018) Routine genetic screening with a multi-gene panel in patients with pheochromocytomas. Endocrine 59(1):175–182
Fishbein L, Merrill S, Fraker DL, Cohen DL, Nathanson KL (2013) Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. Ann Surg Oncol 20(5):1444–1450
Jamilloux Y, Favier J, Pertuit M, Delage-Corre M, Lopez S, Teissier M-P et al (2014) A MEN1 syndrome with a paraganglioma. Eur J Hum Genet 22(2):283–285
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval
This study was approved by the Ethics Committee of the study’s reference hospital, and the participation of other hospitals was approved by the appropriate competent entities.
Informed consent
Informed consent was obtained from all individual participant included in the genetic analyses.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Torres-Costa, M., Flores, B., Torregrosa, N. et al. Malignant prediction in paragangliomas: analysis for clinical risk factors. Langenbecks Arch Surg 406, 2441–2448 (2021). https://doi.org/10.1007/s00423-021-02222-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00423-021-02222-9